F2RL1 and non-small cell lung carcinoma: We found that there was a strong synergic effect of P2pal-18S and gefitinib in PC-9 and PC-9-GR cells by in-vitro scratch wound healing and transwell migration assay (Figures 2A–E), indicating that PAR2 inhibition exerted a significant enhancement of gefitinib in inhibiting NSCLC cell migration.